CurrentUnitedHealthcarePolicy CS334KS.01

Prostate Surgeries and Interventions (for Kansas Only)

Medical policy governing coverage and medical necessity of various prostate surgeries and interventions for members in Kansas, including ablation, cryoablation, urethral lift, water vapor thermotherapy, water jet ablation, biodegradable spacer placement, and prostate artery embolization.

Policy Summary

PayerUnitedHealthcare

PolicyProstate Surgeries and Interventions (for Kansas Only)

Policy CodePolicy CS334KS.01

Change TypeNo material change

Effective DateJun 1, 2025

Next Review DateN/A

Key ActionObtain prior authorization that documents indication, prior therapies, prostate volume and symptom scores and reference InterQual criteria where required.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

KansasPolicy application state

multipleInterventions addressed

YesInterQual referenced

21%PAE retreatment rate (2 yrs)

181Aquablation RCT (WATER I)

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage and Medical Necessity Criteria

Prostatic Urethral Lift (PUL / UroLift) — Coverage Criteria

Prostatic urethral lift (PUL) is covered when ALL of the following FDA‑labeled indications and absence of listed contraindications are met:

ALL of the following

Indication: Treating symptoms due to urinary outflow obstruction secondary to benign prostatic hyperplasia (BPH), including lateral and median lobe hyperplasia, in men 45 years of age or older.
Patient selection: Symptoms consistent with bothersome lower urinary tract symptoms (LUTS) attributable to BPH (e.g., elevated IPSS) and candidate for a minimally invasive procedure per treating clinician.
Contraindications and exclusions: none of the following are present: prostate volume > 100 cc; active urinary tract infection; urethral conditions that prevent insertion of the delivery system into the bladder; urinary incontinence due to incompetent sphincter; current gross hematuria; any anatomic or clinical condition that, in the treating physician's judgment, would preclude safe device delivery (for example severe urethral stricture).
Providers should document prostate volume measurement and absence of the listed contraindications prior to authorization.
Device use: Device implanted and used according to FDA labeled indications, Instructions for Use, and manufacturer warnings/precautions.

High‑Energy Water Vapor Thermotherapy (Rezūm) — Coverage Criteria

High‑energy water vapor thermotherapy (Rezūm and similar systems) is covered when ALL of the following InterQual medical necessity criteria are met:

ALL of the following

Indication: Treatment of lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH).
Clinical criteria: Symptoms refractory to or intolerant of medical therapy, and clinically appropriate candidate for a minimally invasive thermal ablation procedure per treating clinician and InterQual criteria.
Prostate anatomy: Prostate size and anatomy compatible with device labeling and InterQual guidance; treatment of median or lateral lobes per device Instructions for Use.
Exclusions: Treatment of malignant prostate tissue (prostate cancer) is not covered; high‑energy water vapor thermotherapy for malignant tissue or other non‑FDA indications is unproven and not medically necessary.

Transurethral Water Jet Ablation (Aquablation) — Coverage Criteria

Transurethral water jet ablation (Aquablation) is covered for the resection and removal of prostate tissue to treat LUTS due to BPH when ALL of the following are met:

ALL of the following

Indication: Lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) for which surgical intervention is indicated and where Aquablation is an appropriate minimally invasive surgical option per treating clinician.
Eligibility: Patients meeting clinical criteria for surgical BPH intervention (e.g., significant symptoms, failure of medical therapy or patient preference for procedural therapy).
Prostate size and anatomy: Prostate size within device or trial-specified ranges (document prostate volume); anatomy amenable to transurethral water jet resection per device IFU and clinician assessment.
Comparative evidence context: Aquablation may be considered based on available RCT and systematic review data showing noninferior symptom relief vs TURP and potential advantages in ejaculatory preservation; document shared decision‑making discussion of alternatives, risks, and benefits.

Transperineal Placement of Biodegradable Material (Perirectal Spacers) — Coverage Criteria and Evidence

Transperineal placement of biodegradable material (perirectal spacers: hydrogel [SpaceOAR/PEG], hyaluronic acid [Barrigel], or PEG‑based balloon systems) is covered as an adjunct to radiotherapy for prostate cancer when ALL of the following are met:

ALL of the following

Indication: Patient undergoing external beam radiotherapy (including intensity‑modulated radiation therapy or stereotactic body radiation therapy) for prostate cancer where separation of the rectum from the prostate is intended to reduce rectal radiation dose and toxicity.
Clinical criteria: Candidate for prostate radiotherapy without contraindications to transperineal spacer placement (e.g., active rectal infection, uncorrected coagulopathy).
Device and technique: Spacer placement performed transperineally under image guidance (transrectal ultrasound or other imaging) in accordance with manufacturer Instructions for Use and treating radiation oncology protocol.
Documentation: Pre‑ and post‑placement imaging or operative notes documenting spacer placement, separation achieved, and absence of placement complications should be included in the medical record prior to radiation planning adjustments.

Prostate Artery Embolization (PAE) — Coverage Criteria and Evidence Summary

Prostate artery embolization (PAE) is covered for LIMITED indications when ALL of the following are met:

ALL of the following

Indications (one or more of the following must be documented): ineligibility for other standard surgical or endoscopic procedures due to surgical constraints (for example very large prostate size) or anesthesia risk/comorbidities; persistent gross hematuria originating from the prostate despite conservative measures; or other documented clinical circumstances where interventional embolization is judged by the treating team to be the most appropriate option.
Patient selection and counseling: Shared decision‑making documentation that discusses comparative effectiveness, higher re‑treatment rates, and potential for inferior objective functional improvements compared with TURP; patient informed consent should reflect these considerations.
Procedural considerations: PAE must be performed by appropriate interventional specialists with imaging documentation of technical success (e.g., bilateral embolization when feasible) and periprocedural management per institutional protocol.

Applicable Codes and Coding Notes

Prior Authorization

Provider Action: Prior Authorization & Documentation

Prior Authorization Recommended. Prior authorization is recommended for perirectal spacer placement, prostate artery embolization (PAE), transperineal laser ablation (TPLA), focal laser ablation (FLA), and other advanced prostate procedures. Providers should submit documentation supporting medical necessity, prior conservative therapy, and relevant imaging or procedure planning details. InterQual criteria should be used where specified by the payer prior to authorization.

InterQual criteria required where applicable — confirm with payer
Prior authorization recommended for spacer placement and PAE
Prior authorization recommended for PAE, TPLA, and FLA
Listing a code in this policy does not imply coverage or reimbursement — benefit terms govern

Denial Risk

Provider Action: Evidence Limitations & Denial Risk

Prior Authorization, Documentation, and Operational Guidance

Prior Authorization

Use InterQual criteria for listed procedures

InterQual clinical coverage criteria must be met for certain procedures (transurethral ablation, cryoablation, and high‑energy water vapor thermotherapy) before medical necessity is established.

Refer to the InterQual® CP: Procedures (Transurethral Ablation, Cryoablation, Prostate) for member‑level criteria.
If InterQual lacks applicable criteria, UnitedHealthcare may use Medical Policies approved by the Kansas Department of Health and Environment.

Prior Authorization

Aquablation prior authorization — document indication and trial context

When requesting prior authorization for aquablation, document the indication and show alignment with trial‑based inclusion elements (LUTS attributable to BPH, prostate size within studied ranges, and prior therapy attempts).

Provide baseline and follow‑up measures used in trials (IPSS, Qmax, PVR, PSA) to support medical necessity.
Document prior medical therapy trials or contraindication to medical therapy as applicable.

Clinical Background and Scope

Benign prostatic hyperplasia (BPH) is a common condition in men over age 50 that can cause lower urinary tract symptoms (LUTS) such as weak stream, urgency, incomplete emptying, and urinary retention. Management ranges from conservative measures and medications to minimally invasive procedures and surgery when symptoms significantly affect quality of life. Several minimally invasive technologies (e.g., water vapor thermotherapy, transurethral water jet ablation/Aquablation, prostatic urethral lift, embolization, and various focal or transperineal ablation approaches) aim to relieve obstruction while minimizing morbidity compared with traditional transurethral resection of the prostate (TURP); evidence strength and durability vary by technology and indication.

Procedures and Term Definitions

Transurethral water jet ablation (Aquabeam) definition

DefinitionA heat-free water jet system used to ablate benign prostate tissue to treat lower urinary tract symptoms (LUTS) due to BPH (Aquabeam Robotic System)

MechanismRobotic, image-guided transurethral delivery of high-velocity saline jet to remove prostate tissue

Indication contextIntended for resection/removal of prostate tissue in males with LUTS due to BPH (FDA 510(k) clearance referenced in document)

Rezūm System (water vapor thermotherapy) definition

DefinitionA thermal water vapor therapy that reduces prostate volume associated with BPH by delivering convective water vapor energy (Rezūm System)

Target tissueReduces central zone and middle lobe hyperplasia associated with BPH

Policy Revision History

2025-06-01policy_effectiveLatest

Policy effective date (CS334KS.01) enacted for Kansas members; policy uses InterQual as primary clinical criteria source and instructs reference to federal, state, or contractual benefit terms.

2024-03-03device_regulatory_note

Aquabeam Robotic System received FDA 510(k) clearance (referenced in policy device/regulatory section) informing device-specific prior authorization considerations.

2023-06-30

Policy Summary

PayerUnitedHealthcare

PolicyProstate Surgeries and Interventions (for Kansas Only)

Policy CodePolicy CS334KS.01

Change TypeNo material change

Effective DateJun 1, 2025

Next Review DateN/A

Key ActionObtain prior authorization that documents indication, prior therapies, prostate volume and symptom scores and reference InterQual criteria where required.

SourceLink

On This Page

Operational note: Device must be used per manufacturer Instructions for Use; preprocedural evaluation (including prostate size assessment and exclusion of active infection) should be documented.

Evidence summary: Randomized and controlled studies (including pivotal SpaceOAR trials and subsequent prospective studies) demonstrate that spacer use increases perirectal spacing, reduces rectal radiation dose, lowers rates of acute and late rectal toxicity, and improves bowel‑related quality of life during and after prostate radiotherapy; benefits have been sustained through reported follow‑up periods in trials.

Exclusions: PAE is not covered for routine use for all BPH patients, for initial standard candidates for TURP or laser enucleation where those options are appropriate, or for indications without sufficient evidence of benefit; PAE for other non‑specified indications is unproven and not medically necessary.

Evidence context: Systematic reviews and randomized trials indicate PAE can improve patient‑reported symptoms and may have short‑term advantages (less blood loss, shorter hospitalization), but generally yields smaller improvements in objective functional measures versus TURP and a higher retreatment rate; the evidence base is limited by heterogeneity and variable long‑term follow‑up, supporting restricted use in selected patients rather than routine adoption.

Documentation and Denial Risk. Listing a code does not guarantee coverage. Evidence limitations for some procedures (for example, small or uncontrolled Aquablation studies and limited long-term data for PAE) increase the risk of coverage denial. Providers should document why standard therapies were inadequate or contraindicated, include trial-based exclusion/inclusion criteria where relevant, and provide rationale if deviating from guideline-informed treatment sequencing.

Small, uncontrolled Aquablation studies noted — document limitations and rationale for use
PAE associated with higher retreatment rates and inferior functional outcomes versus TURP in some trials — document patient selection and counseling
Evidence limitations may lead to coverage denial — provide robust documentation

Step Therapy

Provider Action: Conservative Therapy & Trial Criteria

Conservative Therapy and Sequencing. Prior to considering advanced procedures, document trials of conservative therapy (e.g., medical management, behavioral measures) as appropriate. Follow guideline-informed treatment sequencing (for example, AUA statements on prostate volume thresholds and device-specific considerations) and note when trial-based exclusion criteria guide eligibility (e.g., prostate volume limits, prior pelvic radiation/surgery, extracapsular extension).

Conservative therapy prior to procedures should be documented
Trial-based exclusion criteria (prostate volume limits, prior radiation/surgery, extracapsular extension) may guide eligibility
Consider requirement to document why standard surgical options (e.g., TURP) are not appropriate when selecting investigational or less-established procedures

Documentation Required

Provider Action: Policy Usage and Documentation

Policy Usage and Operational Notes. Use this policy to guide documentation, coding selection, and prior authorization submission. When codes are listed for reference, confirm coverage with member benefit terms. Include pre-procedure imaging, procedure planning (e.g., for spacer placement), InterQual criteria results if used, and patient counseling regarding risks including potential need for retreatment (notably higher with PAE in some studies).

Policy usage and documentation: include imaging, InterQual results, conservative therapy attempts, and informed consent discussing retreatment risk
Consider requirement to document why standard surgical options are not suitable when requesting coverage for investigational or less-established therapies

Prior Authorization

Prior authorization recommended for spacers and PAE

Prior authorization is recommended for perirectal spacer placement and prostate artery embolization (PAE); include clinical indication, prostate volume and symptom scores, prior treatments, and counseling documentation.

For spacers: document intent to reduce rectal dose during prostate radiotherapy and imaging guidance used (TRUS/US/CT/MRI).
For PAE: document prior therapies, rationale for embolization (eg, ineligibility for other procedures), and informed discussion of risks and higher retreatment rates compared with TURP.

Prior Authorization

Device‑specific prior authorization — reference FDA status

Prior authorization should reference device FDA status and labeled indications when applicable; include documentation aligning the requested use with device labeling or pivotal trial populations.

Cite device regulatory pathway (e.g., 510(k), De Novo, PMA) and the device's labeled indications in the request.
Provide clinical documentation that matches device labeling or trial inclusion criteria.

Prior Authorization

Criteria source for prior authorization — InterQual primary

UnitedHealthcare uses InterQual® as the primary source for medical/surgical criteria; when InterQual does not have applicable criteria, UnitedHealthcare may use its Kansas‑approved Medical Policies for authorization decisions.

Follow InterQual criteria for member‑level medical necessity determinations.
If InterQual lacks criteria for the request, reference UnitedHealthcare Medical Policies approved by the Kansas Department of Health and Environment.

Step Therapy

Document conservative therapy prior to procedures

Conservative management (lifestyle modification and medication) should be documented as tried or considered before submitting requests for minimally invasive BPH procedures when applicable.

Document trials of guideline‑directed medical therapy and lifestyle measures in the record prior to procedural authorization.
Include reasons for failure or intolerance to medical therapy if proceeding to device‑based interventions.

Step Therapy

Step therapy considerations — TURP sequencing and alternatives

Consider TURP as the reference surgical standard and document sequencing of minimally invasive options; authorization requests should explain why alternative standard surgical or guideline‑recommended options were not appropriate when applicable.

If selecting aquablation or other minimally invasive options, document rationale versus TURP and prior treatment history.
Reference AUA/EAU guideline statements when explaining treatment sequencing for the member.

Prior Authorization

Document why TURP is unsuitable before PAE approval

When requesting PAE, document why standard surgical options (for example TURP) are unsuitable for the patient due to comorbidity, anatomic, or other contraindications given reports of inferior functional outcomes and higher retreatment rates after PAE.

Provide clinical rationale and comorbidity justification if deferring TURP in favor of PAE.
Include counseling that 21% of PAE patients in a trial required TURP within 2 years.

Step Therapy

Step therapy preference — document failed medical management or non‑surgical candidacy

Many device studies enrolled patients who had failed medical management or were poor surgical candidates; consider requiring documentation of prior medical therapy failure or non‑surgical candidacy when authorizing device interventions.

Provide baseline IPSS and objective measures showing failure of medical therapy or high surgical risk.
Indicate why the member is not a candidate for standard surgical options if applicable.

Documentation Required

Guideline‑informed treatment sequencing — reference AUA/EAU

Use guideline statements (AUA/EAU) to inform treatment sequencing and document alignment with those recommendations when applicable to the member’s prostate size and anatomy.

Cite the specific guideline recommendation used to justify therapy selection (eg, prostate volume ranges for PUL, waterjet, or water vapor therapies).
Document how the member meets guideline‑based criteria or why deviation is clinically justified.

Note

No explicit step therapy requirement in policy excerpt

No explicit step therapy mandates are stated in this policy excerpt; do not assume formal step therapy is required unless specified by the member’s benefit plan or contract.

Check the member’s federal, state, or contractual benefit terms for any plan‑specific step therapy requirements.
Document any plan‑specific requirements before proceeding with authorization.

Documentation Required

Image guidance required for spacer placement — document modality

Transperineal placement of biodegradable spacers and balloon spacers are performed with image guidance (transrectal ultrasound) and are visualizable on CT/MRI/ultrasound; include procedural image guidance in documentation.

State the imaging modality used for transperineal placement (eg, TRUS, ultrasound) in the operative note.
Attach or reference procedural imaging when available.

Documentation Required

Recommended clinical documentation — baseline and follow‑up measures

Provide baseline and follow‑up clinical measures to support authorization requests, including IPSS, Qmax, PSA, post‑void residual (PVR), prostate volume, and sexual function scores where relevant.

Include baseline IPSS and follow‑up IPSS or other validated symptom scores.
Provide uroflowmetry (Qmax), PVR, prostate volume measurements (TRUS/MRI), and PSA results.

Documentation Required

Document indication and contraindications for spacers and PAE

When seeking authorization for spacers or PAE include the specific indication and any contraindications or intent (eg, intent to reduce rectal dose during radiotherapy or contraindication to TURP).

For spacers: document planned radiotherapy and rationale for spacer placement.
For PAE: document indication such as ineligibility for other procedures or persistent gross hematuria.

Documentation Required

Required clinical documentation — trial‑based elements

Required clinical documentation commonly includes baseline IPSS, QoL, Qmax, PVR, prostate volume, PSA, prior treatments, and the rationale relative to inclusion/exclusion criteria reported in trials.

Provide prior procedure history and reasons for selecting the proposed intervention versus trial/label criteria.
Include any exclusionary findings (eg, active UTI, PVR >300 mL, PSA >10 without negative biopsy) or a negative biopsy when indicated.

Documentation Required

Device trial documentation — baseline measures and rationale

For device trials and device‑based authorizations, provide baseline IPSS, Qmax, prostate volume, PVR, prior procedures, and a rationale comparing the patient to trial inclusion/exclusion criteria.

Explain how the patient meets device labeling/trial thresholds (eg, IPSS, Qmax, prostate volume) or justify deviations.
Attach relevant imaging or biopsy reports when required by the device indication.

Documentation Required

Check federal/state/contractual benefit terms before authorization

Reviewers and providers must check applicable federal, state, and contractual benefit plan requirements because they govern coverage in case of conflict with this policy.

Verify plan‑specific terms before approving or billing for services.
Document which governing benefit terms were applied in the authorization decision.

Denial Risk

Cryoablation evidence heterogeneity — justify selection

Heterogeneous reporting and inconsistent outcomes for cryoablation may lead to denials when documentation does not clearly justify selection of cryoablation or expected oncologic outcomes.

When requesting cryoablation, document biopsy‑proven recurrent disease and rationale for salvage therapy.
Provide clear oncologic outcome expectations and prior treatment history to support medical necessity.

Denial Risk

Aquablation evidence limitations — risk of denial without support

Limited and small uncontrolled aquablation evidence outside pivotal trials may lead to coverage denial if used outside supported indications or without documentation of prior therapies and informed consent.

Document that the patient falls within studied prostate size ranges and trial inclusion criteria when applicable.
Provide informed consent noting device‑specific evidence limitations.

Denial Risk

PAE comparative outcomes — document retreatment risk

PAE has demonstrated higher retreatment rates and inferior functional outcomes compared with TURP at 2 years in randomized trials; authorization should address these limitations in the clinical justification.

Include counseling documentation that 21% of PAE patients required TURP within 2 years in one trial.
Provide rationale for selecting PAE over TURP given comparative outcomes.

Denial Risk

Evidence limitations may trigger noncoverage for PAE/TPLA/FLA

Insufficient, mixed, or short‑term evidence for PAE, TPLA, and focal laser ablation can lead to noncoverage; prior authorization should include documentation of prior medical therapy failure and informed consent acknowledging investigational elements.

Provide objective measures and prior treatment history to show medical necessity.
Attach informed consent that describes limited evidence and uncertain long‑term outcomes.

Denial Risk

Trial‑based exclusion criteria may affect eligibility

Trial exclusion criteria (for example: prior prostate procedures, PSA >10 without negative biopsy, active UTI, PVR >300 mL) commonly used in device trials may guide eligibility and can lead to denial if not addressed.

Confirm and document absence of exclusionary conditions or provide justification/proof (eg, negative biopsy for PSA >10).
Address active infections, high PVR, or prior procedures in the authorization request.

Documentation Required

Governance and coverage conflicts — apply governing benefit terms

In the event of a conflict between this policy and federal, state, or contractual benefit terms, the federal/state/contractual requirements govern; failure to apply the correct governing terms can result in denial.

Document which governing benefit terms (federal/state/contract) were referenced for the authorization decision.
Check plan documents before finalizing coverage determinations.

Clinical contextOffered as a minimally invasive option to relieve LUTS while aiming to preserve sexual function in selected patients

Transperineal biodegradable spacer definition

DefinitionTransperineal injection or placement of biodegradable material (eg, PEG hydrogel, hyaluronic gel, or balloon spacer) between prostate and rectum to reduce rectal radiation dose during prostate radiotherapy

Materials/examplesSpaceOAR hydrogel (PEG), Barrigel (hyaluronic gel), and BioProtect balloon spacer

Imaging and absorptionPlaced under transrectal ultrasound guidance, visualizable on CT/MRI/ultrasound, and absorbed/removed over time

Prostate artery embolization (PAE) definition

DefinitionEndovascular injection of microspheres into prostatic arteries to occlude blood flow, causing gradual prostate shrinkage to alleviate LUTS from BPH (PAE)

Procedure settingPerformed by interventional radiology under image guidance using embolic microspheres (eg, Embosphere)

Indication contextConsidered for patients ineligible for other procedures or with persistent gross hematuria originating from the prostate

Phoenix definition (biochemical recurrence)

DefinitionThe Phoenix definition refers to a standard biochemical recurrence definition after prostate cancer treatment used to define recurrence in cryoablation studies (ASTRO Phoenix definition)

Use in studiesApplied in cryoablation literature to report recurrence intervals and biochemical-free survival

Reported recurrence intervalsStudies using Phoenix definition reported recurrence ranges across included series (documented in systematic review)

IPSS definition

DefinitionInternational Prostate Symptom Score (IPSS) — a validated patient-reported questionnaire measuring LUTS severity used as a primary endpoint in BPH trials

Typical trial thresholdsFrequently used enrollment thresholds include IPSS ≥10 (iTind) or ≥13 (Optilume) depending on study

RoleUsed to document baseline symptom burden and treatment effect over follow-up in device trials

Aquablation definition (image-guided robotic water jet ablation)

DefinitionImage-guided, robotic-assisted transurethral water jet tissue ablation for BPH (also referred to as Aquablation/Aquabeam)

TechniqueRobotic targeting with real-time imaging to direct a heat-free high-velocity water jet to remove obstructing prostate tissue

Evidence contextRandomized trials (eg, WATER I) and single-arm studies evaluated Aquablation for prostates generally up to ~80 mL in RCTs

Perirectal spacer / SpaceOAR definition

DefinitionPerirectal spacer (eg, SpaceOAR) — a biodegradable hydrogel or hyaluronic acid material placed transperineally between the prostate and rectum to reduce rectal radiation dose during prostate radiotherapy

Clinical effectReduces rectal dosimetry and GI toxicity, with documented improvements in bowel QOL in randomized trials

Placement and imagingInserted under transrectal ultrasound guidance and visible on CT/MRI; absorbs over time

Prostate artery embolization (PAE) definition (endovascular embolization)

DefinitionEndovascular embolization of the prostatic arteries with microspheres to occlude blood flow, inducing prostate shrinkage and symptom relief (PAE)

Embolic agentsIncludes Embosphere microspheres and other embolic products cleared or De Novo authorized for prostatic embolization

Comparative contextCompared with TURP in trials showing short-term benefits but generally inferior long-term functional outcomes and higher retreatment rates in some studies

Focal laser ablation (FLA) definition

DefinitionFocal laser ablation (FLA) — targeted thermal ablation treating MRI-visible tumor foci within the prostate to spare surrounding gland and potentially reduce urinary/sexual dysfunction compared to whole-gland therapies

Evidence statusCurrent evidence is insufficient for routine use; recommended within clinical trials or prospective studies

Indication considerationsSuitability depends on tumor volume, location, grade group, MRI visibility, and biopsy confirmation

Transperineal laser ablation (TPLA) definition

DefinitionTransperineal laser ablation (TPLA) — a minimally invasive transperineal approach delivering laser energy via optical fiber to ablate prostate tissue for LUTS/BPH

Technique and guidanceDelivered through the perineum under transrectal ultrasound guidance; aims to improve Qmax, PVR, and IPSS

Evidence statusInsufficient long-term evidence; pilot studies show symptomatic improvements but larger RCTs are needed

iTind (temporary urethral stent) definition

DefinitioniTind — a temporarily implanted nitinol device placed in the prostatic urethra to restore urine flow; removable device evaluated for short- to mid-term symptom relief

Trial inclusionRCTs enrolled men ≥50 years with IPSS ≥10, Qmax ≤12 mL/sec, and prostate volume generally 25–75 cc

Evidence contextRCT data show symptom improvement in many patients but mixed statistical significance on some primary endpoints; durability variable across studies

IPSS (duplicate trial definition reference)

Definition (trial context)International Prostate Symptom Score (IPSS) — patient-reported measure of LUTS severity used as a primary endpoint in trials (duplicate reference to trial enrollment thresholds)

Common useServes as baseline and follow-up metric in device studies to document symptom burden and improvement

Example thresholdsUsed to determine eligibility and response (eg, ≥10 or ≥13 depending on study)

Qmax definition (peak urinary flow rate)

DefinitionQmax — peak urinary flow rate measured in mL/sec during uroflowmetry, used as an objective endpoint in BPH device studies

Trial useOften used as an inclusion criterion (eg, Qmax ≤12 mL/sec or 5–12 mL/sec ranges) and outcome measure in trials

Clinical interpretationLower Qmax indicates greater obstruction; improvements post-procedure signal functional benefit

Device regulatory designations (510(k), De Novo, PMA) as used in policy

510(k) clearanceFDA 510(k) Premarket Notification pathway referenced for devices such as Aquabeam and rectal spacers (document cites K202961 and 510(k) clearances)

De Novo classificationDe Novo pathway cited for devices such as Embosphere microspheres (DEN160040) and iTind (DEN190020) in document examples

PMA approvalPMA pathway referenced for devices such as the Spanner temporary prostatic stent (PMA P060010); policy notes device-specific FDA status should inform authorization

device_regulatory_note

Optilume Urethral Drug Coated Balloon received FDA clearance (referenced in policy device/regulatory section) informing device-specific prior authorization considerations.